Long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera: a post-marketing study

Authors

Tomoko Hayashi (ORCID: https://orcid.org/0000-0002-9589-8348)
Wataru Hongo
Weizhe Lu

Institutions

Novartis (Switzerland) (CH)
Novartis (Japan) (JP)

Publication Details

Journal: Future Oncology
Published: 2025-11-28
DOI: https://doi.org/10.1080/14796694.2025.2595691
Primary Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera: a post-marketing study

Tomoko Hayashi, Wataru Hongo, Weizhe Lu

Nov 28, 2025

Future Oncology

Myeloproliferative Neoplasms: Diagnosis and Treatment

article

Long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera: a post-marketing study

Tomoko Hayashi, Wataru Hongo, Weizhe Lu

November 28, 2025article en

Abstract

No abstract available for this paper.

Future OncologyVol. 21(30)

Novartis (Switzerland) (CH), Novartis (Japan) (JP)

Openalex Percentile: Top 46%

Myeloproliferative Neoplasms: Diagnosis and Treatment

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera: a post-marketing study — Tomoko Hayashi, Wataru Hongo, et al. · Future Oncology (2025) | TGRS Research Map | TGRS